Ifimed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 23-10-2024
- Paid Up Capital ₹ 2.50 M
as on 23-10-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.31 Cr
as on 23-10-2024
- Revenue 5.69%
(FY 2023)
- Profit -27.19%
(FY 2023)
- Ebitda -17.22%
(FY 2023)
- Net Worth 30.32%
(FY 2023)
- Total Assets 7.18%
(FY 2023)
About Ifimed Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹4.31 Cr.
Anantharamaiah Sudeendra and Prabhudev Pavithra serve as directors at the Company.
- CIN/LLPIN
U51397KA2012PTC065239
- Company No.
065239
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Aug 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Mysore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Ifimed Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anantharamaiah Sudeendra  | Managing Director | 09-Aug-2012 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prabhudev Pavithra | Director | 09-Aug-2012 | Current |
Financial Performance of Ifimed Pharmaceuticals.
Ifimed Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.69% increase. The company also saw a substantial fall in profitability, with a 27.19% decrease in profit. The company's net worth Soared by an impressive increase of 30.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ifimed Pharmaceuticals?
In 2023, Ifimed Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 03 May 2024 | ₹3.48 Cr | Open |
Hdfc Bank Limited Creation Date: 15 Sep 2022 | ₹0.78 M | Open |
Hdfc Bank Limited Creation Date: 31 Aug 2021 | ₹1.51 M | Open |
How Many Employees Work at Ifimed Pharmaceuticals?
Ifimed Pharmaceuticals has a workforce of 38 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ifimed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ifimed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
